INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10661641
Filing Date		2003-09-15
First Named Inventor	Burke	e T. Barrett
Art Unit		3762
Examiner Name	Scott	M. Getzow
Attorney Docket Numb	er	1000.026

				U.S.	PATENTS	Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	5861014		1999-01-19	Famion	
	2	5836994		1997-11-17	Bourgeois	
	3	5611350		1997-03-18	John	
	4	5571150		1996-11-05	Wernicke, et al.	
	5	5540734		1996-07-30	Zabara	
	6	5540730		1996-07-30	Terry, Jr., et al.	
	7	5423872		1995-06-13	Cigaina	
	8	5299569		1994-04-05	Wernicke, et al.	

	Application Number		10661641	
INFORMATION DIGGI COURT	Filing Date		2003-09-15	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Burke		e T. Barrett	
(Not for submission under 37 CFR 1.99)	Art Unit		3762	
(,	Examiner Name	Scott	M. Getzow	
	Attorney Docket Numb	er	1000.026	

	9	5263480	1993-11-23	Wernicke, et al.	
	10	5199430	1993-04-06	Fang, et al.	
	11	5188104	1993-02-23	Wernicke, et al.	
	12	5025807	1991-06-25	Zabara	
	13	4867164	1989-09-19	Zabara	
	14	4702254	1987-10-27	Zabara	
If you wis	h to a	dd additional U.S. Paten		ease click the Add button.	Add Remove
Examiner Initial*	Cite No	Publication Number	Publication	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20050131486	2005-06-16	Boveja, et al.	
	2	20050049655	2005-03-03	Boveja, et al.	
	3	20050004621	2005-01-06	Boveja, et al.	

		Application Number			10661641			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		Filing Date			2003-09-15			
		First Named Inventor Burke		e T. Barrett				
		Art Unit			3762			
(1401 101 54511	ission under or or it i	,	Examiner Name Scot		Scott	t M. Getzow		
			Attorney Docket Number			1000.026		

4	20050154425	2005-07-14	Boveja, et al.	
5	20030236558	2003-12-25	Whitehurst, et al.	
6	20050192644	2005-09-01	Boveja, et al.	
7	20060079936	2006-04-13	Boveja	
8	20040172094	2004-09-02	Cohen, et al.	
9	20050131485	2005-06-16	Knudson, et al.	
10	20050038484	2005-02-17	Knudson, et al.	
11	20040172088	2004-09-02	Knudson, et al.	
12	20040167583	2004-08-26	Knudson, et al.	
13	20040172085	2004-09-02	Knudson, et al.	
14	20040176812	2004-09-09	Knudson, et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10661641		
Filing Date		2003-09-15		
First Named Inventor Burke		T. Barrett		
Art Unit		3762		
Examiner Name	Scott	M. Getzow		
Attorney Docket Number		1000 026		

	15	20040172091		2004-09-0		Rezai					
	16	20030181954		2003-0	9-25	Rezai					
	17	20020151939		2002-10-17		Rezai					
If you wish	h to a	dd additional U.S. Publi						d buttor			
				FOREIG	ON PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³				Publication Date	Name of Patente Applicant of cited Document	e or	where Rele	or Relevant	Τs
	1	2004036377	wo	wo		2004-04-29	Osorio, et al.				
	2	2005007120	wo	wo		2005-01-27	Lesser				
If you wish	h to a	dd additional Foreign Pa	tent Do	cument	citation	information pl	ease click the Add	button	Add		
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner Initials*	Cite No	Include name of the au (book, magazine, journ publisher, city and/or of	nal, seri:	al, symp	osium,	catalog, etc), o					T5
	1		BACHMAN, D.S. et al. "Effects of Vagal Volleys and Serolonin on Units of Cingulate Cortex in Monkeys," Brain								
	2	ELGER, G., et al., "Vagu Research 42 (2000) 203		Stimulati	ion is As	sociated with M	ood Improvements in	n Epileps	sy Patients,*	Epilepsy	

INFORMATION DISCLOSURE FIRM Date STATEMENT BY APPLICANT (Not for submission under 37 GFR 1.99)

Att Unit Examiner Na Attorney Doc

	Application Number		10661641				
	Filing Date		2003-09-15				
	First Named Inventor Burk		T. Barrett				
	Art Unit		3762				
	Examiner Name Scott		M. Getzow				
	Attorney Docket Numb	er	1000.026				
_							

3	FISHER, R.S., et al., "Reassessment: Vagus Nerve Stimulation for Epitepsy," Neurology Vol. 53 (September 1999) 666-669	
4	HALLOWITZ, R.A., et al., "Effects of Viagal Volleys on Units of Intrateminar and Juxtalaminar Thalamic Nuclei in Monkeys," Brain Research 130 (1977) 271-286	
5	HENRY, T.R., "Therapeutic Mechanisms of Vagus Nerve Stimulation," Neurology 59 (Suppl.4) (September 2002) S3-S14	
6	KRAHL, S.E., et al., "Destruction of Peripheral C-Fibers Does Not Alter Subsequent Vagus Nerve Stimulation-Induced Sezure Suppression in Rats," Epilepsia 42(5): 596-589 (2001)	
7	LABAR, D., et al., "Vagus Nerve Stimulation for Medication-Resistant Generalized Epilepsy," Neurology 52 (April 1999) 1510-1512	
8	LOCKARD, J.S., et at, "Feasibility and Safety of Vegal Sitrulation in Monkey Model," Epilepsia 31 (Suppl.2): S20- S26 (1990)	
9	ROSENBAUM, J., et al., "Vagus Nerve Stimulation for Treatment-Resistant Depression," Society of Biological Psychiatry, Vol. 47, No. 4 (February 15, 2009)	
10	SALINSKY, M.C., et al., "Vagus Nerve Stimulation for the Treatment of Medically Intractable Seizures," Arch Neurol. Vol. 53 (November 1996) 1176-1179	
11	SCHACHTER, S.C. and Schmidt D., eds. "Vagus Nerve Stimulation," Martin Dimitz Ltd., Publisher, London (2001) pp 1-101	
12	TERRY, R.S., et al., "The implantable Neurocybernetic Prosthesis System," Pacing and Clinical Electrophysiology, Vol. 14, No. 1 (January 1991) 95-93	
13	VONCK, K., et al., "The Mechanism of Action of Vagus Nerve Stimulation for Refractory Epilepsy," Journal of Neurophysiology, Vol. 18, No. 5 (September 2001) 384-401	

	14	WOCDBURY, J.W., et al., "Vagail Stimulation Reduces the Sevenity of Maximal Electroshock Seizures in Intact Rats; Use of Cuff Electrode for Stimulating and Recording," PACE, Vol. 14 (January 1991) 94-107	
	15	ZABARA, J., et al., "Inhibition of Experimental Seizures in Canines by Repetitive Vagal Stimulation," Epilepsia 33 (6):1005-1012 (1992)	
If you wis	h to ar	d additional non-patent literature document citation information please click the Add button Add	1

EXAMINER SIGNATURE

Date Considered

Date Considered

PEXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patient Documents at work_USPTO.GDV or MPEP 901.04. ² Entire office that issued the document, by the two-letter code (WIPO Standard STS, ³ For Japanese plent documents, and enclusion of the year of the eight of the Emperor must precede the sent number of the patient document. Plant of the patient document code with one of the patient document. ³ Applicate the patient accounted code with one of the patient document code with one of the patient code

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10661641		
Filing Date		2003-09-15		
First Named Inventor	Burke	T. Barrett		
Art Unit		3762		
Examiner Name Scott		M. Getzow		
Attorney Docket Number		1000.026		

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s);

	That each item of information contained in the information disclosure statement was first cited in any communication
П	from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
_	information disclosure statement. See 37 CFR 1 97(e)(1)

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/5(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/9/(c).

Fee set forth in 37	CFR 1.17 (p) has been	submitted herewith.

7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Carol G. Mintz/	Date (YYYY-MM-DD)	2006-09-20	
Name/Print	Carol G. Mintz	Registration Number	38561	

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is foll field end by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, U.S. Operatment of Commence, P. 0. Bot 1450, Alexandria, V.3231-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. 0. Box 1450, Alexandria, V.2231-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, during an inspection of records conducted by GSA a part of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.